The abstract is read at the publisher; the summary is JClub's.
HCV RNA prevalence among people who inject drugs in France fell from 29.6% to 14.5% between 2013 and 2023, alongside a drop in incidence from 6.5 to 2.4 per 100 person-years.
- Why it matters: Accurate incidence and prevalence estimates are needed to guide prevention and care to meet WHO HCV elimination goals, especially in people who use and inject drugs where transmission persists.
- What they did: Cross-sectional surveys in France (2004, 2013, 2023) recruited PWUD at harm reduction services and collected behavioral and biological data; HCV antibody and HCV RNA prevalence were modeled with multivariate regression, while incidence was estimated using two-state transmission models.
- The result: Among all PWUD, HCV RNA prevalence declined from 19.4% (95% CI 16.3–23.0) to 9.5% (7.2–12.3), and among PWID incidence decreased from 6.5 (4.1–8.0) to 2.4 (1.4–4.2) per 100 person-years, implying substantial progress but ongoing transmission.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.